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Abstract
Recent studies have revealed that BRCA1 and BRCA2 germline mutation-related breast cancers show frequent
overexpression of hypoxia inducible factor-1a (HIF-1a), the key regulator of the hypoxia response. However, the question
remained whether hypoxia is a late stage bystander or a true carcinogenetic event in patients with hereditary
predisposition. We therefore studied HIF-1a overexpression in ductal carcinoma in situ (DCIS), an established precursor of
invasive breast cancer. We used immunohistochemistry to examine the expression of the hypoxia markers HIF-1a, CAIX
and Glut-1 in DCIS and available invasive carcinoma lesions of 32 BRCA1, 16 BRCA2 and 77 non-BRCA mutation-related cases.
HIF-1a expression was detected in 63% of BRCA1 and 62% of BRCA2 as compared to 34% of non-BRCA mutation-related
DCIS cases (p = 0.005). CAIX overexpression was present in 56% of BRCA1 and 44% of BRCA2 as compared to 6% of non-BRCA
mutation-related DCIS cases (p = 0.000). Glut-1 overexpression was observed in 59% of BRCA1, 75% of BRCA2 and 67% of
non-BRCA mutation-related DCIS cases (p = 0.527). Overall, HIF-1a, CAIX and Glut-1 expression in BRCA mutation-related
DCIS matched the expression in the accompanying invasive cancers in 60% or more of cases. In non-BRCA mutation-related
cases the expression of the hypoxia markers in DCIS matched the expression in the invasive part in 46% or more of the
cases. Although BRCA1 and BRCA2 germline mutation-related invasive breast cancers are different in many ways, the
hypoxia-related proteins HIF-1a, CAIX and Glut-1 are expressed in both DCIS and invasive lesions of BRCA1 and BRCA2
mutation carriers. This suggests that hypoxia may already play a role in the DCIS stage of BRCA1 and BRCA2 germline
mutation related breast carcinogenesis, and may also drive cancer progression. Hypoxia-related proteins are therefore
putative targets for therapy and molecular imaging for early detection and monitoring therapy response in BRCA mutation
patients.
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Introduction
Hereditary breast cancer accounts for about 5% of all breast
cancers in women and is primarily caused by a germline mutation
in one of the BRCA genes. Several studies have indicated that the
genetic makeup of BRCA1 and BRCA2 mutation-related breast
cancer is different from that of non-BRCA mutation-related breast
cancer. These differences comprise gains and losses of specific
parts of chromosomes, as well as differences in protein expression
[1–7]. Consistent with this, the morphological and immunohisto-
chemical phenotype of BRCA1 mutation-related breast cancer is
also different from that of non-BRCA mutation-related breast [8–
13]. However, the phenotype of BRCA2 mutation-related breast
cancer is still difficult to distinguish from non-BRCA mutation-
related breast cancers [14,15].
Hypoxia is a hallmark of many non-BRCA mutation-related
breast cancer types [16]. Hypoxia inducible factor-1 (HIF-1) is the
key regulator of the hypoxia response. HIF-1 consists of 2 subunits,
HIF-1a and HIF-1b. While HIF-1b is constitutively expressed, the
HIF-1a protein is continuously degraded under normoxia by the
ubiquitin-proteasome pathway [17,18]. Under hypoxia, HIF-1a
protein degradation is inhibited resulting in its overexpression,
subsequent binding to HIF-1b [19] and downstream signalling
[20]. In non-BRCA mutation-related breast cancer, HIF-1a
overexpression plays a role in carcinogenesis [21–26] and
correlates with poor prognosis [27,28]. When HIF-1a is overex-
pressed, established downstream targets like Carbonic anhydrase
IX (CAIX) and Glucose transporter-1 (Glut-1) are also up
regulated [29,30]. BRCA1 seems to play a role in the hypoxic
response by regulating HIF-1a stability and by modulating
expression of vascular endothelial growth factor, a major
downstream target of HIF-1a [31]. Furthermore, functional
HIF-1a overexpression (mostly hypoxia induced) is seen at a
much higher frequency in BRCA1 mutation-related invasive breast
cancer than in sporadic breast cancer [32,33]. In contrast, BRCA2
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mutation-related invasive cancers express HIF-1a less frequently
[33].
However, studies in pre-invasive lesions are required to address
the question whether hypoxia is a late stage bystander or a true
carcinogenetic event.
There is both clinical and experimental evidence to suggest that
ductal carcinoma in situ (DCIS) is a precursor lesion to most, if not
all, non-BRCA mutation-related invasive breast cancers [34–38].
DCIS and other premalignant lesions such as lobular neoplasia,
fibroadenoma, and ductal hyperplasia seems to be more common
in prophylactic mastectomy (PM) specimens of BRCA1 and BRCA2
mutation carriers than in control mammoplasty specimens [10,39–
42]. Furthermore, DCIS lesions adjacent to invasive cancers in
BRCA mutation carriers have been described [43,44]. DCIS in
BRCA mutation carriers is often high grade [43] and shows a
similar morphology and immunophenotype as the accompanying
invasive cancer [45]. High grade DCIS of non-BRCA-related cases
often shows central necrosis [46] indicative of hypoxia. Indeed,
overexpression of hypoxia-related proteins HIF-1a, CAIX and
Glut-1 DCIS of non-BRCA mutation carriers has been described
[22]. To find clues whether changes in hypoxia related proteins
also is an early event in BRCA mutation-related carcinogenesis, we
evaluated HIF-1a expression in BRCA1 and BRCA2 mutation-
related DCIS in relation with the accompanying invasive cancers.
Materials and Methods
Patients
The study group comprised DCIS lesions of 32 patients with
pathogenic germline BRCA1 mutations, 16 patients with patho-
genic germline BRCA2 mutations and 77 patients unselected for
family history (further denoted ‘‘non-BRCA mutation-related’’). A
synchronous invasive tumor was also present in 28 BRCA1, 17
BRCA2 and 50 non-BRCA mutation-related cases. Tissue from
these patients was available from our own archives, and from
different pathology laboratories in The Netherlands (St Antonius
Hospital Nieuwegein, Diakonessenhuis Utrecht, Gelre Ziekenhui-
zen Apeldoorn, Rijnstate Arnhem, Stichting Pathologisch en
Cytologisch laboratorium West Brabant Bergen op Zoom,
Ziekenhuis Gelderse Vallei Ede, Deventer Ziekenhuis Deventer,
Meander medisch centrum Amersfoort, Onze Lieve Vrouwe
Gasthuis Amsterdam, the VU University Medical Center,
Amsterdam and the University Medical Center Groningen). Since
we used archival pathology material which does not interfere with
patient care and does not involve the physical involvement of the
patient, no ethical approval is required according to Dutch
legislation [the Medical Research Involving Human Subjects Act
(Wet medisch-wetenschappelijk onderzoek met mensen, WMO
[47])]. Use of anonymous or coded left over material for scientific
purposes is part of the standard treatment contract with patients
and therefore informed consent procedure was not required
according to our institutional medical ethical review board. This
has also been described by van Diest et al. [48].
Histopathology
Tumor size was measured in the fresh resection specimens, and
tumor samples were subsequently fixed in neutral buffered
formaldehyde, and processed to paraffin blocks according to
standard procedures. Four mm thick sections were cut and stained
with H&E for histopathology. Tumor type was assessed according
to the WHO 2003, and tumors were graded according to the
Nottingham grading system. Mitoses counting was performed as
previously described [49]. Scoring was performed by one observer
(PJvD) who was blinded to the origin of the tumors.
Immunohistochemistry
After deparaffinization and rehydration, antigen retrieval was
performed using EDTA buffer at boiling temperature for
20 minutes for ER, HER2 and HIF-1a. A cooling period of
30 minutes preceded the incubation of the slides for HIF-1a with
protein block (Novolink Max Polymer detection system, ready to
use, Novocastra Laboratories Ltd, Newcastle Upon Tyne, UK) for
5 minutes at room temperature. Incubation of the slides with the
HIF-1a mouse monoclonal (BD Biosciences, Pharmingen, Lex-
ington, MA, USA), was done at a dilution of 1:50 overnight at
4uC. For detection, a polymer (Novolink Max Polymer detection
system, ready to use) was used. For ER and HER2, the slides were
incubated with primary antibodies for ER (1:100, Dako) and
HER2 (1:100, Neomarkers) 60 minutes at room temperature.
For PR, Glut-1 and CAIX, antigen retrieval was performed in
citrate buffer, pH=6.0, for 20 minutes at 100uC. A cooling period
of 30 minutes preceded the incubation (60 minutes at room
temperature) with the primary antibodies. Polyclonal primary
antibodies used were: PR (1:100, Dako), Glut-1 (1:200, DAKO)
and CAIX (1:1000, Abcam, Cambridge Science Park, Cambridge,
UK). For detection of the primary antibodies against ER, PR,
HER2, CAIX and Glut-1, a poly HRP anti- Mouse/Rabbit/Rat
IgG (ready to use, ImmunoLogic, Duiven, Netherlands) was used.
All slides were developed with diaminobenzidine (10 minutes)
followed by hematoxylin counterstaining. Before the slides were
mounted all sections were dehydrated in alcohol and xylene.
Positive controls were used throughout, negative controls were
obtained by omission of the primary antibodies from the staining
procedure. Representative pictures of positive and negative
controls for HIF-1a, CAIX and Glut-1 have been provided as
Figure S1.
Scoring of immunohistochemistry was performed by one
observer (PJvD). HIF-1a was regarded overexpressed when
.1% of nuclei were positive as described before [26]. ER and
PR expression was regarded positive when 10% or more of the
tumor nuclei stained positive. HER2 was scored positive when a
3+ membrane staining was observed according to the Dako
system. CAIX and Glut-1 stainings were scored positive when a
clear membrane staining pattern was seen. Associations between
stainings were tested by Chi-square analysis. P-values,0.05 were
considered to be statistically significant.
Results
The clinicopathological characteristics and expression of ER,
PR, HER2, HIF-1a, CAIX and Glut-1 of BRCA1, BRCA2 and non-
BRCA mutation-related DCIS cases are described in Table 1. The
age of onset is lower in BRCA compared to non-BRCA mutation
carriers (p = 0.000). BRCA1 mutation-related DCIS cases often are
ER, PR and HER2-negative as compared to the BRCA2 and non-
BRCA mutation-related DCIS (see Table 1 for correlations).
Expression of hypoxia-induced proteins in BRCA1, BRCA2
and non-BRCA mutation-related DCIS
HIF-1a overexpression was observed in 63% (20/32) of the
BRCA1, in 62% (10/16) of the BRCA2 and in 34% (26/77) of the
non-BRCA mutation-related DCIS cases (p = 0.005;Table 1).
CAIX overexpression was observed in 56% (18/32) of BRCA1
mutation-related DCIS cases, with accompanying HIF-1a over-
expression in 31% (10/32) of the cases (p = 0.358;Table 2). Glut-1
was overexpressed in 59% (19/32) of the BRCA1 mutation-related
DCIS cases and HIF-1a was co-overexpression in 41% (13/32) of
these cases (p = 0.403).
HIF-1a Expression in BRCA Mutation Related DCIS
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CAIX was expressed in 44% (7/16) of BRCA2 mutation-related
DCIS cases with accompanying HIF-1a overexpression in 38%
(6/16) of the cases (p = 0.091). Glut-1 overexpression was observed
in 75% (12/16) of BRCA2 mutation-related DCIS cases, with HIF-
1a co-overexpression in 56% (9/16) of the cases (p = 0.074).
In the non-BRCA mutation-related DCIS cases, CAIX expres-
sion was seen in 6% (5/77) of the cases which were negative for
HIF-1a. Glut-1 was overexpressed in 67% (52/77) of non-BRCA
mutation-related DCIS cases, with concomitant HIF-1a overex-
pression in 29% (22/77) of the cases (p = 0.022).
Furthermore, in the BRCA1 and BRCA2 mutation-related DCIS
no correlations between HIF-1a expression and grade, ER, PR
and HER2 expression were found. For the non-BRCA mutation-
related DCIS cases, a positive trend was observed with grade, and
a negative trend with ER (Table 2).
Expression of hypoxia-induced proteins in BRCA1, BRCA2
and non-BRCA mutation-related DCIS and invasive
cancer
In the BRCA1 mutation-related cases with DCIS and concom-
itant invasive cancer (N=29), the frequency of HIF-1a overex-
pression was high in both lesions: 62% (18/29) and 83% (24/29),
respectively (p = 0.264;Table 3.). The frequency of CAIX expres-
sion was 52% (15/29) and 79% (23/29), respectively, in DCIS and
invasive carcinoma (p= 0.311). Further, 59% (17/29) of the DCIS
and 83% (24/29) (p = 0.945) of the invasive lesions were positive
for Glut-1 expression. Examples of these IHC results are shown in
Figure 1.
In the BRCA2 mutation-related cases with invasive counterparts
(N= 16), 63% (10/16) of DCIS lesions were HIF-1a positive as
compared to 38% (6/16) if invasive lesions (p = 0.016). The same
expression of CAIX was observed in BRCA2 mutation-related
DCIS lesions and the invasive counterpart lesions, 44% (7/16)
Table 1. Clinicopathological characteristics and expression of
ER, PR, HER2, HIF-1a, CAIX and Glut-1 in DCIS lesions of BRCA1,
BRCA2 and non-BRCA mutation carriers.
BRCA1 BRCA2 non-BRCA p-value
N 32 16 77
Age ,45 25(78%) 9(56%) 14(18%)
.45 7(22%) 7(44%) 63(82%) 0.000
Grade 1 0(0%) 1(6%) 11(14%)
2 9(28%) 8(50%) 30(39%)
3 23(72%) 7(44%) 36(47%) 0.035
ER neg 22(69%) 4(25%) 19(25%)
pos 10(31%) 12(75%) 58(75%) 0.000
PR neg 27(84%) 9(56%) 36(47%)
pos 5(16%) 7(44%) 41(53%) 0.002
HER2 neg 31(97%) 11(69%) 55(71%)
pos 1(3%) 5(31%) 22(29%) 0.014
HIF-1a neg 12(38%) 6(38%) 51(66%)
pos 20(63%) 10(62%) 26(34%) 0.005
CAIX neg 14(44%) 9(56%) 72(94%)
pos 18(56%) 7(44%) 5(6%) 0.000
Glut-1 neg 13(41%) 4(25%) 25(33%)
pos 19(59%) 12(75%) 52(67%) 0.527
doi:10.1371/journal.pone.0056055.t001
Table 2. Correlation of HIF-1a expression in DCIS lesions of BRCA1, BRCA2 and non-BRCA mutation carriers with age, grade, ER, PR,
HER2, CAIX and Glut-1 expression in these lesions.
BRCA1 BRCA2 non-BRCA
N 32 16 77
HIF-1a p-value HIF-1a p-value HIF-1a p-value
neg pos neg pos neg pos
Age ,45 9 16 3 6 8 6
.45 3 4 0.740 3 4 0.696 43 20 0.427
Grade 1 0 0 1 0 10 1
2 2 7 4 4 21 9
3 10 13 0.264 1 6 0.149 20 16 0.081
ER neg 8 14 1 3 9 10
pos 4 6 0.844 5 7 0.551 42 16 0.045
PR neg 10 17 4 5 22 14
pos 2 3 0.900 2 5 0.515 29 12 0.373
HER2 neg 12 19 5 6 39 16
pos 0 1 0.431 1 4 0.330 12 10 0.170
CAIX neg 4 10 5 4 46 26
pos 8 10 0.358 1 6 0.091 5 0 0.099
Glut-1 neg 6 7 3 1 21 4
pos 6 13 0.403 3 9 0.074 30 22 0.022
doi:10.1371/journal.pone.0056055.t002
HIF-1a Expression in BRCA Mutation Related DCIS
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(p = 0.049). Glut-1 was overexpressed in 75% (12/16) of DCIS
cases in and in 56% (9/16) (p = 0.146) of the invasive BRCA2
mutation-related lesions (Table 3).
The frequency of HIF-1a expression in non-BRCA mutation-
related DCIS and concomitant invasive cancer (N= 50) was 38%
(19/50) and 34% (17/50), respectively (p = 0.029). Similar CAIX
expression was observed in both lesions, 8% (4/50) and 12% (6/
50), respectively (p = 0.015). Glut-1 overexpression was seen in
70% (35/50) of DCIS cases and in 36% (18/50) (p = 0.797) of the
invasive non-BRCA mutation-related lesions.
In summary, these non-significant differences indicate that HIF-
1a positivity was similar in DCIS and the accompanying invasive
lesions. Differences in HIF-1a expression between BRCA1 and
BRCA2 and non-BRCA mutation related DCIS were borderline
significant (p = 0.062). A significant difference in HIF-1a expres-
sion was seen between BRCA1 and BRCA2 as compared to non-
BRCA mutation-related invasive cancer (p = 0.000).
Expression of hypoxia-induced proteins in BRCA non-
BRCA mutation-related DCIS vs invasive cancer
Table 4 shows the expression of HIF-1a, CAIX and Glut-1 in
paired, DCIS and concomitant invasive cancer, for BRCA
mutation and non-BRCA mutation carriers.
HIF-1a expression was expressed in both lesions in 55% (16/29)
of the BRCA1 mutation-related cases, whereas both lesions were
negative for HIF-1a expression in 10% (3/29) of cases. Overall, in
66% (19/29) of the BRCA1 mutation carrier cases both lesions
showed similar expression levels of HIF-1a. In 28% (8/29) of the
BRCA1 mutation-related cases only the invasive part, and in 7%
(2/29) only the DCIS lesion showed HIF-1a expression. CAIX
and Glut1 were expressed in both lesions in 45% (13/29) and 48%
(14/29) of the BRCA1 mutation carrier cases, respectively, and
both lesions lacked expression of these markers in 14% (4/29) and
7%(2/29) of the cases. Thereby, CAIX was concomitantly
expressed in both lesions 59% (17/29) of the cases, and the
Glut-1 in 55% (16/29). Only the invasive lesion of BRCA1
mutation carriers expressed both CAIX and Glut-1 in 34% (10/
29) of cases. Expression of CAIX and Glut-1 exclusively in BRCA1
mutation-related DCIS lesions was observed in 7% (2/29) and
10% (3/29) of cases, respectively.
In the BRCA2 mutation-related cases with DCIS and concom-
itant invasive cancer, 38% (6/16) of the cases HIF-1a expression
was observed and was absent in 38% (6/16) of the cases (Table 4).
Thus, in 75% (12/16) of the BRCA2 mutation-related cases, the
DCIS and invasive lesions of the same patient showed similar
expression levels of HIF-1a. Expression of HIF-1a in only the
DCIS lesion was seen in 25% (4/16) of the BRCA2 mutation-
related cases. CAIX was expressed in both lesions in 31% (5/16) of
BRCA2 mutation-related cases and in 44% (7/16) of the cases both
lesions lacked expression (total match 75%). CAIX was expressed
in the invasive, but not in the DCIS part in 13% (2/16) of the
cases, and CAIX was expressed in the DCIS, but not in the
invasive part of 13% (2/16) of the cases. Glut-1 was expressed or
absent in both lesions in 50% (8/16) and 19% (3/16) of cases,
respectively (total match 69%). Further, Glut-1 expression was
confined to the invasive part in 6% (1/16) of cases and the DCIS
part in 25% (4/16) of the cases.
HIF-1a was expressed in both lesions in 20% (10/50) of the
non-BRCA mutation-related cases and both lesions lacked HIF-1a
expression in 48% (24/50) of cases. Thus, in total, 68% (34/50) of
the non-BRCA mutation carrier cases showed similar expression
levels of HIF-1a in both lesions. In 14% (7/50) of the non-BRCA
mutation-related cases only the invasive part, and in 18% (9/50)
only the DCIS lesion showed HIF-1a expression. CAIX and Glut-
1 were expressed in both lesions in 4% (2/50) and 26% (13/50),
respectively, of the non-BRCA mutation carrier cases. Conversely,
both lesions lacked CAIX expression in 84% (42/50) and Glut-1
Figure 1. Immunohistochemical staining of HIF-1a, CAIX and Glut-1 in normal breast tissue (A, D and G), DCIS (B, E and H) and
concomitant invasive cancer (C, F and I) of a BRCA1 mutation carrier.
doi:10.1371/journal.pone.0056055.g001
HIF-1a Expression in BRCA Mutation Related DCIS
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expresssion in 20%(10/50) of these cases. Thereby, CAIX
expression in both lesions matched in 88% (44/50) and Glut-1
expression in 46% (23/50) of cases. Expression of CAIX and Glut-
1 in only the invasive lesion of non-BRCA mutation carriers
occurred in 8% (4/50) and 10% (5/50) of cases, respectively,
whereas these markers were expressed only in DCIS lesions in 4%
(2/50) and 44% (22/50) of cases.
When BRCA1 and BRCA2 mutation-related cases were exam-
ined together, HIF-1a expression in DCIS matched the expression
in the accompanying invasive cancers in 68% (31/45) of cases, as
compared to in 68% (34/50) of the non-BRCA mutation carrier
cases. The expression of CAIX matched in 64% (29/45) of BRCA1
and BRCA2 mutation-related cases, as compared to in 88% (44/
50) of non-BRCA mutation carrier cases. For Glut-1, the
expression in DCIS matched the expression in the accompanying
invasive cancers in 60% (27/45) of BRCA1 and BRCA2 mutation-
related cases as compared to 46% (23/50) for non-BRCA mutation
carrier cases.
Discussion
Non-BRCA mutation-related DCIS lesions, especially high
grade ones, are known to become centrally deprived of oxygen
resulting in activation of the hypoxia pathway, as shown in several
studies by the presence of HIF-1a and its downstream targets. The
aim of the present study was to examine the expression of HIF-1a
in DCIS lesions of BRCA1 and BRCA2 mutation carriers in
comparison with their invasive counterparts. Activation of HIF-1a
in the DCIS stage of BRCA1 or BRCA2 germline mutated patients
would indicate that hypoxia is an early driver of BRCA mutation-
related carcinogenesis. HIF-1a overexpression was indeed fre-
quently observed in BRCA1 and BRCA2 mutation-related DCIS
cases, in association with expression of its downstream genes,
indicating that HIF-1a is active.
Overall, 63% (30/48) of BRCA mutation-related DCIS lesions
were HIF-1a-positive, which was significantly different compared
to non-BRCA mutation carriers (34%, 26/77). The latter figure is
Table 3. Clinicopathological characteristics and expression of
ER, PR, HER2, HIF-1a, CAIX and Glut-1 in DCIS and





BRCA BRCA1 BRCA2 non-BRCA
N 29 16 50 29 16 50
Age ,45 21 8 8
.45 8 8 42
Type ductal 27 15 45
lobular 1 0 3
other 1 1 2
Grade 1 0 1 8 0 1 7
2 4 7 20 8 8 19
3 25 8 22 21 7 24
ER neg 22 4 13 21 4 13
pos 7 12 37 8 12 37
PR neg 25 5 19 25 9 26
pos 4 11 31 4 7 24
HER2 neg 26 13 39 28 11 33
pos 3 3 11 1 5 17
HIF-1a neg 5 10 33 11 6 31
pos 24 6 17 18 10 19
CAIX neg 6 9 44 14 9 46
pos 23 7 6 15 7 4
Glut-1 neg 5 7 32 12 4 15
pos 24 9 18 17 12 35
doi:10.1371/journal.pone.0056055.t003




neg pos p-value neg pos p-value neg pos p-value
DCIS neg 3 8 4 10 2 10
pos 2 16 0.264 2 13 0.311 3 14 0.945
BRCA2 Invasive
HIF-1alpha CAIX Glut-1
neg pos p-value neg pos p-value neg pos p-value
DCIS neg 6 0 7 2 3 1
pos 4 6 0.016 2 5 0.049 4 8 0.146
non-BRCA Invasive
HIF-1alpha CAIX Glut-1
neg pos p-value neg pos p-value neg pos p-value
DCIS neg 24 7 42 4 10 5
pos 9 10 0.029 2 2 0.015 22 13 0.797
doi:10.1371/journal.pone.0056055.t004
HIF-1a Expression in BRCA Mutation Related DCIS
PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e56055
lower compared to our earlier observations where 67% of sporadic
DCIS lesions were HIF-1a positive [22]. Nevertheless, the current
study suggests that hypoxia and HIF-1a already play a similar role
in the DCIS stage of BRCA mutation-related carcinogenesis as in
non-BRCA mutation-related DCIS.
BRCA mutation-related invasive cancers (especially BRCA1
mutation-related ones) more frequently show HIF-1a overexpres-
sion than non-BRCA mutation-related ones [33,34]. This suggests
that hypoxia plays a more important role in cancer progression in
BRCA mutation carriers than in non-BRCA mutation carriers.
HIF-1a, CAIX and Glut-1 expression in BRCA mutation-related
DCIS was usually similar in the accompanying invasive lesions.
This implies that next to being involved in early BRCA mutation-
related carcinogenesis, hypoxia and HIF-1a overexpression may
also be a driver of cancer progression, especially in BRCA1
mutation carriers. Although the number of BRCA2 mutation-
related cases with DCIS and invasive lesions was small, there was a
trend towards higher expression of the hypoxia-related markers in
BRCA2 mutation-related DCIS as compared to the invasive
lesions. We can speculate that progression to the invasive state in
these BRCA2 mutation carriers might be due to the switch of the
HIF-1a to HIF-2a expression under prolonged hypoxia [50]. HIF-
2a expression has been observed in sporadic breast cancer [51]
and should be analysed in BRCA mutation-related breast cancer
and pre-invasive lesions. As HIF-1a already plays a role in the pre-
invasive lesions of BRCAmutation carriers, hypoxia proteins would
therefore be putative therapeutic targets for prevention of invasive
disease. HIF-1a signalling inhibitors like PX-478 [52], farnesyl-
transferase inhibitor R115777 or trans-farnesylthiosalicyclic acid
[53,54], Cetuximab [55] and other antibodies with the same
structural motif [56], 2-methoxyestradiol (2ME2) [57,58], and
inhibitors of the RNA binding protein Hur [59,60] are some of the
therapeutics currently available.
We conclude that BRCA1 and BRCA2 germline mutation-
related DCIS show a high frequency of overexpression of HIF-1a
and its downstream proteins CAIX and Glut-1, as compared to
non-BRCA mutation-related DCIS. This suggests that hypoxia
may already play a role at the DCIS stage of BRCA1 and BRCA2
germline mutation-related breast carcinogenesis, and may also
drive cancer progression. The current findings could be clinically
relevant for BRCA mutation- related breast cancer treatment in
several ways. First, HIF-1a and its downstream effectors may be
used as molecular imaging targets for early detection and
monitoring of therapy response. Second, HIF-1a is an interesting
therapeutic target at the pre-invasive stage of BRCA mutation-
related breast disease to prevent invasive disease.
Supporting Information
Figure S1 Positive controls: Immunohistochemical staining of
HIF-1a and CAIX in renal clear cell carcinoma (B and D) and for
Glut-1 in placental tissue (F). In A, C and E the primary antibody
was omitted to provide negative controls.
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